Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment… Read more
Monte Rosa Therapeutics Inc (GLUE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.409x
Based on the latest financial reports, Monte Rosa Therapeutics Inc (GLUE) has a cash flow conversion efficiency ratio of 0.409x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($100.43 Million) by net assets ($245.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Monte Rosa Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Monte Rosa Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Monte Rosa Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Monte Rosa Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Turkiye Sigorta AS
IS:TURSG
|
0.086x |
|
Shenzhen Jove Enterprise Co. Ltd.
SHE:300814
|
0.051x |
|
H2O Retailing Corporation
PINK:HTOCF
|
N/A |
|
Harvia Oyj
PINK:HRVFF
|
0.123x |
|
Center Laboratories
TWO:4123
|
0.002x |
|
Zhangjiagang Guangda Special Material Co Ltd
SHG:688186
|
-0.021x |
|
Zhejiang Jiangshan Chemical Co Ltd
SHE:002061
|
0.111x |
|
LMW Limited
NSE:LMW
|
N/A |
Annual Cash Flow Conversion Efficiency for Monte Rosa Therapeutics Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Monte Rosa Therapeutics Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $222.94 Million | $42.00 Million | 0.188x | +177.09% |
| 2023-12-31 | $179.25 Million | $-43.80 Million | -0.244x | +28.27% |
| 2022-12-31 | $271.41 Million | $-92.47 Million | -0.341x | -99.44% |
| 2021-12-31 | $347.51 Million | $-59.36 Million | -0.171x | -136.11% |
| 2020-12-31 | $-48.73 Million | $-23.05 Million | 0.473x | -6.90% |
| 2019-12-31 | $-12.15 Million | $-6.17 Million | 0.508x | -- |